Patents by Inventor Joseph Thomas Repine

Joseph Thomas Repine has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 2-(pyridin-2-ylamino)-pyrido[2,3, d]pyrimidin-7-ones
    Patent number: 7456168
    Abstract: The present invention provides substituted 2-aminopyridines useful in treating cell proliferative disorders. The novel compounds of the present invention are potent inhibitors of cyclin-dependent kinases 4 (cdk4).
    Type: Grant
    Filed: April 11, 2007
    Date of Patent: November 25, 2008
    Assignee: Warner-Lambert Company
    Inventors: Mark Barvian, Richard John Booth, John Quin, III, Joseph Thomas Repine, Derek J. Sheehan, Peter Laurence Toogood, Scott Norman Vanderwel, Hairong Zhou
  • 7-(4-(4-[3-CHLORO-2-(TRIFLUOROMETHYL)PHENYL]PIPERAZIN-1-YL)BUTOXY)-[1,8]-NAPHTHYRIDIN-2(1H)-ONE
    Publication number: 20080167319
    Abstract: This invention relates to a compound of formula (I) or pharmaceutically acceptable salts thereof, pharmaceutical compositions containing the compound or a salt thereof, and its use as a medicament for the treatment of schizophrenia, bipolar disorder, or other central nervous system disorders.
    Type: Application
    Filed: January 2, 2008
    Publication date: July 10, 2008
    Inventors: David Alan Favor, Joseph Thomas Repine
  • 2-(pyridin-2-ylamino)-pyrido [2,3-d]pyrimidin-7-ones
    Patent number: 7208489
    Abstract: The present invention provides substituted 2-aminopyridines useful in treating cell proliferative disorders.
    Type: Grant
    Filed: January 28, 2005
    Date of Patent: April 24, 2007
    Assignee: Warner-Lambert Company
    Inventors: Mark Barvian, Richard John Booth, John Quin, III, Joseph Thomas Repine, Derek J. Sheehan, Peter Laurence Toogood, Scott Norman Vanderwel, Hairong Zhou
  • [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
    Patent number: 7160888
    Abstract: This invention relates to compounds of the formula 1 wherein G, D, A, Z, Q, X, Y, R1, and R4 through R7 are defined as in the specification, processes for preparing the same and intermediates used in making the same, and pharmaceutical compositions containing such compounds and their use in the treatment of central nervous system disorders and other disorders.
    Type: Grant
    Filed: July 28, 2004
    Date of Patent: January 9, 2007
    Assignee: Warner Lambert Company LLC
    Inventors: Douglas S. Johnson, Joseph Thomas Repine, Andrew David White
  • 2-thia-1,6,8-triaza-naphthalene-2,2-dioxides are kinase inhibitors
    Patent number: 7026313
    Abstract: The present invention provides 2-thia-1,6,8-triaza-naphthalene-2,2-dioxide inhibitors of cyclin-dependent kinases, uses thereof and pharmaceutical compositions thereof. These compounds are useful for treating cell proliferative disorders, such as cancer, atherosclerosis, and restenosis. These compounds are potent inhibitors of kinases such as cyclin-dependent (cdks) and growth factor-mediated kinases.
    Type: Grant
    Filed: January 21, 2003
    Date of Patent: April 11, 2006
    Assignee: Warner-Lambert Company
    Inventor: Joseph Thomas Repine
  • 5-substituted tetralones as inhibitors of ras farnesyl transferase
    Patent number: 6943183
    Abstract: The present invention provides novel 5-substituted tetralones of Formulas I, II, III, and IV and pharmaceutically acceptable salts, esters, amides, and prodrugs thereof, which are useful for treating and preventing uncontrolled or abnormal proliferation of tissues, such as cancer, atherosclerosis, restenosis, and psoriasis.
    Type: Grant
    Filed: April 16, 2001
    Date of Patent: September 13, 2005
    Assignee: Pfizer Inc
    Inventors: William Alexander Denny, Richard H. Hutchings, Douglas S. Johnson, James Stanley Kaltenbronn, Ho Huat Lee, Daniele Marie Leonard, Jared Bruce John Milbank, Joseph Thomas Repine, Gordon William Rewcastle, Andrew David White
  • 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones
    Patent number: 6936612
    Abstract: The present invention provides substituted 2-aminopyridines useful in treating cell proliferative disorders.
    Type: Grant
    Filed: January 16, 2003
    Date of Patent: August 30, 2005
    Assignee: Warner-Lambert Company
    Inventors: Mark Barvian, Richard John Booth, John Quin, III, Joseph Thomas Repine, Derek J. Sheehan, Peter Laurence Toogood, Scott Norman Vanderwel, Hairong Zhou
  • 2-Aminopyridine substituted heterocycles
    Publication number: 20040236084
    Abstract: The present invention provides substituted 2-aminopyridines of formula I, wherein R1, A1, W, X, and Y are as defined in the specification, useful in treating cell proliferative disorders.
    Type: Application
    Filed: January 16, 2004
    Publication date: November 25, 2004
    Applicant: Pfizer Inc
    Inventors: Cathlin Marie Biwersi, Dennis Joseph McNamara, Joseph Thomas Repine, Peter Laurence Toogood, Scott Norman Vanderwel, Joseph Scott Warmus
  • Dihydro-2H-naphthalene-1-one inhibitors of ras farnesyl transferase
    Publication number: 20040171844
    Abstract: Disclosed are compounds of the Formula I 1
    Type: Application
    Filed: February 19, 2004
    Publication date: September 2, 2004
    Inventors: Daniele Marie Leonard, Joseph Thomas Repine, Gordon William Rewcastle
  • 5- substituted tetralones as inhibitors of ras farnesyl trransferase
    Publication number: 20040044057
    Abstract: The present invention provides novel 5-substituted tetralones of Formulas (I), (II), (III) and (IV) and pharmaceutically acceptable salts, esters, amides, and prodrugs thereof, which are useful for treating and preventing uncontrolled or abnormal proliferation of tissues, such as cancer, atherosclerosis, restenosis, and psoriasis. Specifically, the present invention relates to compounds that inhibit the farnesyl transferase enzyme.
    Type: Application
    Filed: May 19, 2003
    Publication date: March 4, 2004
    Inventors: William Alexander Denny, Richard H Hutchings, Douglas S Johnson, James Stanely Kaltenbronn, Ho Huat Lee, Daniele Marie Leonard, Jared Bruce John Milbank, Joseph Thomas Repine, Gordon William Rewcastle, Andrew David White
  • Dihydro-2h-napthalene-1-one inhibitors of ras farnesyl transferase
    Publication number: 20030232790
    Abstract: The present invention provides dihydro-2H-napthalene-1-ones of formula (V), and pharmaceutically acceptable salts, esters, amides, and prodrugs thereof, which are useful for treating and preventing uncontrolled or abnormal proliferation of tissues, such as cancer, atherosclerosis, restenosis, and psoriasis. Specifically, the present invention relates to compounds that inhibit the farnesyl transferase enzyme.
    Type: Application
    Filed: October 8, 2002
    Publication date: December 18, 2003
    Inventors: Daniele Marie Leonard, Joseph Thomas Repine, Gordon William Rewcastle
  • 2-Thia-1,6,8-Triaza-Naphthalene-2,2-Dioxides are kinase inhibitors
    Publication number: 20030186973
    Abstract: The present invention provides 2-thia-1,6,8-triaza-naphthalene-2,2-dioxide inhibitors of cyclin-dependent kinases, uses thereof and pharmaceutical compositions thereof.
    Type: Application
    Filed: January 21, 2003
    Publication date: October 2, 2003
    Inventor: Joseph Thomas Repine
  • 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones
    Publication number: 20030149001
    Abstract: The present invention provides substituted 2-aminopyridines useful in treating cell proliferative disorders. The novel compounds of the present invention are potent inhibitors of cyclin-dependent kinases 4 (cdk4).
    Type: Application
    Filed: January 16, 2003
    Publication date: August 7, 2003
    Inventors: Mark Barvian, Richard John Booth, John Ouin, Joseph Thomas Repine, Derek J. Sheehan, Peter Laurence Toogood, Scott Norman Vanderwel, Hairong Zhou
  • Certain benzothiazine dioxide endothelin antagonists and processes for their preparation
    Publication number: 20030073684
    Abstract: The instant invention is a series of benzothiazine dioxides, or a pharmaceutically acceptable salt thereof, which are potent endothelin A antagonists with profound in vitro activity, and improved syntheses for the Formula 1 1
    Type: Application
    Filed: June 3, 2002
    Publication date: April 17, 2003
    Inventors: Amy Mae Bunker, Xue-Min Cheng, Annette Marian Doherty, Jeremy John Edmunds, Gerald David Kanter, Chitase Lee, Joseph Thomas Repine, Richard William Skeean
  • Certain benzothiazine dioxide endothelin antagonists and processes for their preparation
    Patent number: 6545150
    Abstract: The instant invention is a series of benzothiazine dioxides, or a pharmaceutically acceptable salt thereof, which are potent endothelin A antagonists with profound in vitro activity, and improved syntheses for the Formula 1 The compounds are useful in treating elevated levels of endothelin, essential renovascular malignant and pulmonary hypertension, cerebral infarction, cerebral ischemia, congestive heart failure, and subarachnoid hemorrhage.
    Type: Grant
    Filed: December 5, 2001
    Date of Patent: April 8, 2003
    Assignee: Warner-Lambert Company
    Inventors: Amy Mae Bunker, Xue-Min Cheng, Annette Marian Doherty, Jeremy John Edmunds, Gerald David Kanter, Chitase Lee, Joseph Thomas Repine, Richard William Skeean
  • Bicyclic inhibitors of protein farnesyl transferase
    Patent number: 6528535
    Abstract: The present invention provide compounds of Formula I The present invention also provides a method of treating cancer and treating or preventing restenosis or atherosclerosis. Also provided by the present invention is a pharmaceutically acceptable composition containing a compound of Formula I.
    Type: Grant
    Filed: July 23, 2001
    Date of Patent: March 4, 2003
    Assignee: Warner-Lambert Company
    Inventors: Jack Bikker, Ellen Myra Dobrusin, Annette Marian Doherty, Matthew Drowns, James Stanley Kaltenbronn, Juergen Kleinschroth, Dennis Joseph McNamara, John Quin, III, Joseph Thomas Repine, Marcin Stasiak
  • Certain benzothiazine dioxide endothelin antagonists and processes for their preparation
    Patent number: 6440962
    Abstract: The instant invention is a series of benzothiazine dioxides, or a pharmaceutically acceptable salt thereof, which are potent endothelin A antagonists with profound in vitro activity, and improved syntheses for the Formula I The compounds are useful in treating elevated levels of endothelin, essential renovascular malignant and pulmonary hypertension, cerebral infarction, cerebral ischemia, congestive heart failure, and subarachnoid hemorrhage.
    Type: Grant
    Filed: March 27, 2001
    Date of Patent: August 27, 2002
    Assignee: Warner-Lambert Company
    Inventors: Amy Mae Bunker, Xue-Min Cheng, Annette Marian Doherty, Jeremy John Edmunds, Gerald David Kanter, Chitase Lee, Joseph Thomas Repine, Richard William Skeean
  • Certain benzothiazine dioxide endothelin antagonists and processes for their preparation
    Publication number: 20020094980
    Abstract: The instant invention is a series of benzothiazine dioxides, or a pharmaceutically acceptable salt thereof, which are potent endothelin A antagonists with profound in vitro activity, and improved syntheses for the Formula 1 1
    Type: Application
    Filed: December 5, 2001
    Publication date: July 18, 2002
    Inventors: Amy Mae Bunker, Xue-Min Cheng, Annette Marian Doherty, Jeremy John Edmunds, Gerald David Kanter, Chitase Lee, Joseph Thomas Repine, Richard William Skeean
  • Bicyclic inhibitors of protein farnesyl transferase
    Publication number: 20020006936
    Abstract: The present invention provides compounds of Formula I 1
    Type: Application
    Filed: July 23, 2001
    Publication date: January 17, 2002
    Inventors: Jack Bikker, Ellen Myra Dobrusin, Annette Marian Doherty, Matthew Drowns, James Stanley Kaltenbronn, Juergen Kleinschroth, Dennis Joseph McNamara, John Quin, Joseph Thomas Repine, Marcin Stasiak
  • 2-(pyridin-2-ylamino)-pyrido[2,3-D]pyrimidin-7-ones
    Patent number: RE47739
    Abstract: The present invention provides substituted 2-aminopyridines useful in treating cell proliferative disorders.
    Type: Grant
    Filed: July 27, 2018
    Date of Patent: November 26, 2019
    Assignee: Warner-Lambert Company LLC
    Inventors: Mark Barvian, Richard John Booth, John Quinn, III, Joseph Thomas Repine, Derek J. Sheehan, Peter Lawrence Toogood, Scott Norman Vanderwel, Hairong Zhou